Article
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Oncotarget - 21 Mar 2017
Nguyen Andrew H, Elliott Irmina A, Wu Nanping, Matsumura Cynthia, Vogelauer Maria, Attar Narsis, Dann Amanda, Ghukasyan Razmik, Toste Paul A, Patel Sanjeet G, Williams Jennifer L, Li Luyi, Dawson David W, Radu Caius, Kurdistani Siavash K, Donahue Timothy R
Abstract excerpt
Although histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs, thus far, they have been unsuccessful in early phase clinical trials for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor efficacy is the tumor stroma, where cancer-associated fibroblasts (CAFs) are a prominent cell type and a source of resistance to cancer therapies. Here, we demonstrate that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.